Splanchnic vein thrombosis as a manifestation of latent myeloproliferative neoplasm associated with sticky platelet syndrome
DOI:
https://doi.org/10.22516/25007440.779Keywords:
Thrombosis, Thrombophilia, Neoplasm, Anticoagulants, hematological diseasesAbstract
Vein thrombosis of unusual sites such as the splanchnic region continues to be not only a diagnostic but also a therapeutic challenge for the clinician due to its manifestation and associated pathologies. Latent JAK2 (Janus kinase 2) positive myeloproliferative neoplasm associated with sticky platelet syndrome is unusual. We present a clinical case of a 38-year-old female patient who presented with sudden onset abdominal pain of a possible vascular origin. Splanchnic thrombosis was diagnosed in latent myeloproliferative neoplasm by identifying the JAK2V617F mutation and sticky platelet syndrome via platelet aggregometry. Off-label anticoagulation with rivaroxaban 20 mg/day was administered. During her outpatient follow-up, she did not suffer any new thrombotic episodes.
Downloads
References
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. https://doi.org/10.1093/eurheartj/ehz405
Salhotra A, Oo TH. JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):4-8. https://doi.org/10.1007/s12288-012-0215-2
Valeriani E, Riva N, Di Nisio M, Ageno W. Splanchnic Vein Thrombosis: Current Perspectives. Vasc Health Risk Manag. 2019;15:449-461. https://doi.org/10.2147/VHRM.S197732
Shah D. Thrombophllia. En: Collier VU (editor). Board basics: An enhancement to MKSAP. 18.a edición. American College of Physicians; 2018. p. 217-219.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133-143. https://doi.org/10.1002/ajh.25303
Goodyer M, Langabeer SE, Haslam K, Murphy K. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis. Pathol Oncol Res. 2016;22(1):229-30. https://doi.org/10.1007/s12253-015-9994-8
Ocampo-Salgado C, Duque-Ramírez M, Serna-Posada M del M, Díaz-Martínez JC, Aristizábal-Aristizábal J. Trombosis venosa subclavia asociada a electrodo de marcapasos y síndrome de la plaqueta pegajosa. Rev Colomb Cardiol. 2018;25(2):154-61. https://doi.org/10.1016/j.rccar.2017.11.029
Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G, Hernández-Reyes J, Vargas-Espinosa J, García-Chavez J, Rosales-Padrón J, et al. Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome. Clin Appl Thromb Hemost. 2015;21(1):91-5. https://doi.org/10.1177/1076029613501543
Ocampo chaparro JM GHA. Abdomen agudo en el anciano. Rev Colomb Cir. 2006;21(4):266-282.
Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(12):1177-1187. https://doi.org/10.1056/NEJMra1700365
Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https://doi.org/10.1038/nrdp.2017.28
Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86-91. https://doi.org/10.1016/j.vph.2018.05.002
Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM, et al. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. Mayo Clin Proc. 2018;93(1):40-47. https://doi.org/10.1016/j.mayocp.2017.10.007
Kubisz P, Holly P, Stasko J. Sticky Platelet Syndrome: 35 Years of Growing Evidence. Semin Thromb Hemost. 2019;45(1):61-68. https://doi.org/10.1055/s-0038-1676581
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
